Auven Therapeutics Announces Sale of Ocular Technologies to Sun Pharma

October 26, 2016
- Ocular Technologies key development program asset, Seciera™ for the treatment of dry eye disease, is close to completing confirmatory Phase 3 clinical trial.
- Auven to receive $40 million upfront payment, substantial contingent development and commercial milestone payments, and royalties.
Read the full press release
Sun's press release

Auven Therapeutics Announces Completion of Enrollment in Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease

August 22, 2016
-Pivotal study to confirm significant improvements in tear production and ocular surface inflammation in patients with dry eye disease, with top-line results anticipated by year-end.
-Seciera poised for significant commercial opportunity as a highly competitive entrant in dry eye disease market.
Read the full press release

Auven Therapeutics Announces Initiation of Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease

March 03, 2016
-Study to confirm significant improvements in tear production as sole primary endpoint to support regulatory filing.
-Commercial assessment confirms Seciera has the potential for $1 billion in sales worldwide
Read the full press release

Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA™ for the Treatment of Orphan Disease AA Amyloidosis

January 21, 2016
Auven Therapeutics, a global private equity company focused on accelerated development of breakthrough therapeutic drugs, and BELLUS Health Inc. (TSX:BLU), a drug development company focused on rare diseases, today announced the completion of the KIACTA™ (eprodisate) Phase 3 confirmatory study for the treatment of AA amyloidosis..
Read the full press release